Kaleido Biosciences Stock Forecast, Price & News

-0.44 (-5.86 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $7.07
50-Day Range
MA: $9.33
52-Week Range
Now: $7.07
Volume17,311 shs
Average Volume299,082 shs
Market Capitalization$300.24 million
P/E RatioN/A
Dividend YieldN/A
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Kaleido Biosciences logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:KLDO
Phone617 674 9000
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$300.24 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable


See More Headlines


Overall MarketRank

1.84 out of 5 stars

Medical Sector

115th out of 2,011 stocks

Biotechnology Industry

11th out of 143 stocks

Analyst Opinion: 3.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
-0.44 (-5.86 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

Is Kaleido Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kaleido Biosciences stock.
View analyst ratings for Kaleido Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Kaleido Biosciences?

Wall Street analysts have given Kaleido Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kaleido Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Kaleido Biosciences

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its earnings results on Tuesday, March, 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.16. The firm earned $0.24 million during the quarter.
View Kaleido Biosciences' earnings history

How has Kaleido Biosciences' stock been impacted by Coronavirus (COVID-19)?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have increased by 27.6% and is now trading at $7.07.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KLDO?

6 brokerages have issued 1-year target prices for Kaleido Biosciences' stock. Their forecasts range from $12.00 to $22.00. On average, they expect Kaleido Biosciences' share price to reach $17.90 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price.
View analysts' price targets for Kaleido Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Mr. Daniel L. Menichella B.A., M.B.A., Pres, CEO & Director (Age 62, Pay $525.7k)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 40)
  • Mr. William E. Duke Jr., Chief Financial Officer (Age 49, Pay $672.87k)
  • Dr. Katharine Knobil M.D., Consultant (Age 56, Pay $695.78k)
  • Dr. Johan van Hylckama Vlieg Ph.D., Chief Scientific Officer (Age 52)
  • Mr. Jerald Korn J.D., Chief Admin. Officer, Gen. Counsel & Corp. Sec. (Age 42)
  • Ms. Susan Stewart J.D., Chief Regulatory Affairs Officer (Age 59)
  • Ms. Clare Fisher, Chief Bus. Officer

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $7.07.

How much money does Kaleido Biosciences make?

Kaleido Biosciences has a market capitalization of $300.24 million.

How many employees does Kaleido Biosciences have?

Kaleido Biosciences employs 82 workers across the globe.

What is Kaleido Biosciences' official website?

The official website for Kaleido Biosciences is

How can I contact Kaleido Biosciences?

The company can be reached via phone at 617 674 9000.

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.